TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21324455
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol with luteal phase E(2) patch
Study: 19243357
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 90 mg after fasting
Study: 16954724
Drug: Zidovudine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (oral and intravenous dosing)
Study: 16954724
Drug: Contraceptive therapy
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive therapy (oral or injectable)
Study: 16954724
Drug: Zidovudine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (oral administration)
Study: 16954724
Drug: Contraceptive therapy
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive therapy
Study: 15159264
Drug: Subcutaneous adjusted-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adjusted-dose unfractionated heparin (UFH)
Study: 15159264
Drug: Fixed-dose low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose low-molecular-weight heparin (nadroparin)
Study: 31435964
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of alfaxalone (10 mg/kg)
Study: 31435964
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of alfaxalone (10 mg/kg)
Study: 27009831
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) 60 mg once daily plus Asunaprevir (ASV) 100 mg twice daily for 12 weeks
Study: 18583470
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg by mouth daily
Study: 1550275
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml propofol (10 mg)
Study: 1550275
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml placebo (Intralipid)
Study: 1550275
Drug: Supplementary dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary dose of 10 mg propofol (for treatment failures in placebo group)
Study: 3897722
Drug: 330 mg
Normalized name: urea 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 330 mg of acetylsalicylic acid (aspirin) plus 75 mg of dipyridamole three times daily
Study: 22858559
Drug: Concurrent ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent ipilimumab
Study: 29303446
Drug: Concurrent ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent ipilimumab with SRS dose ≥ 20 Gy
Study: 25189328
Drug: Educational programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational programme based on the Health Belief Model (HBM), consisting of four 1-hour sessions twice per week
Study: 19147137
Drug: PID patients
Normalized name: PID
DrugBank: Phenindione (DB00498)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PID patients with myeloperoxidase G/A alleles
Study: 19147137
Drug: PID patients
Normalized name: PID
DrugBank: Phenindione (DB00498)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PID patients with G/G homozygous alleles
Study: 11287776
Drug: Pyridoxine 100
Normalized name: pyridoxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine 100 mg/day
Study: 18476391
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate tablet 100 mg (Control)
Study: 15650846
Drug: Ziprasidone (IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (IM up to 3 days, then oral 40-80 mg, b.i.d.)
Study: 15650846
Drug: Haloperidol (IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (IM up to 3 days, then oral 5-20 mg/day)
Study: 7552502
Drug: IDUs enrolled
Normalized name: IdU
DrugBank: Idoxuridine (DB00249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDUs enrolled in the HIV vaccine trial
Study: 2349198
Drug: Nebulised fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised fenoterol (5 mg)
Study: 2349198
Drug: Nebulised terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised terbutaline (5 mg)
Study: 1757610
Drug: 0.05% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% betamethasone dipropionate cream
Study: 387495
Drug: 0.025% fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% fluocinolone acetonide cream
Study: 16960411
Drug: Carvedilol therapy
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol therapy (6.25 mg/day uptitrated to 23.9 +/- 13.9 mg)
Study: 12670065
Drug: At-home treatment
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home treatment with 10% carbamide peroxide
Study: 12670065
Drug: In-office treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office treatment with 35% hydrogen peroxide
Study: 12670065
Drug: At-home treatment
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At-home treatment
Study: 12670065
Drug: In-office treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office treatment
Study: 1555086
Drug: alpha‐ketoisocaproate (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐ketoisocaproate (17 g day‐1)
Study: 1555086
Drug: branched chain
Normalized name: Branched Chain Amino Acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: branched chain solution (3.3 g nitrogen day‐1)
Study: 1555086
Drug: balanced amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: balanced amino acid solution (no further supplements)
Study: 31272834
Drug: Mokuboito plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mokuboito plus standard therapy
Study: 26301603
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antihypertensive treatment (n=199)
Study: 26301603
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antihypertensive treatment (n=186)
Study: 26301603
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antihypertensive treatment
Study: 23839180
Drug: Duac® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duac® Gel (BPO 5%‐clindamycin phosphate 1.2%)
Study: 23839180
Drug: Acanya® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acanya® Gel (BPO 2.5%‐clindamycin phosphate 1.2%)
Study: 23839180
Drug: Aczone® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aczone® Gel (dapsone 5%)
Study: 23839180
Drug: Epiduo® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epiduo® Gel (BPO 2.5%‐adapalene 0.1%)
Study: 16440121
Drug: Nebulized terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbutaline plus intravenous betamethasone
Study: 15571785
Drug: Family-focused psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused psychoeducational treatment for bipolar adolescents (FFT-A) combined with mood stabilizing medications
Study: 11810324
Drug: Harpagophytum extract
Normalized name: Harpagophytum procumbens whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harpagophytum extract LI 174 (Rivoltan(R)) 2x480 mg/day for 4 weeks
Study: 29311137
Drug: AZD7325 (4‐amino‐8‐(2‐fluoro‐6‐methoxyphenyl)‐N‐propylcinnoline‐3‐carboxamide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7325 (4‐amino‐8‐(2‐fluoro‐6‐methoxyphenyl)‐N‐propylcinnoline‐3‐carboxamide) administered orally, repeated doses over a period not specified.
Study: 25342205
Drug: DEX 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 1.0 µg/kg 5 min before propofol injection (group VII)
Study: 22145513
Drug: Ramtace 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramtace 10 mg (test product)
Study: 10981566
Drug: 0.5 microg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microg/ml sufentanil
Study: 10981566
Drug: 0.75 microg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 microg/ml sufentanil
Study: 10981566
Drug: 1 microg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg/ml sufentanil
Study: 9024262
Drug: Ovine CRH
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine CRH (oCRH) injection during desmopressin (DP) infusion
Study: 9024262
Drug: Ovine CRH
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine CRH (oCRH) injection during saline (SAL) infusion
Study: 9024262
Drug: Desmopressin (DP)
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin (DP) infusion plus SAL injection
Study: 9024262
Drug: SAL injection
Normalized name: Mepivacaine Hydrochloride 30 mg in 1 mL SUBMUCOSAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAL injection during SAL infusion
Study: 8453023
Drug: Dolasetron administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron administered orally at doses ranging from 50 to 400 mg (mesylate monohydrate)
Study: 16432050
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg/day
Study: 8068472
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg/day
Study: 3142400
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (at D 90)
Study: 29320595
Drug: 1060 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1060 nm laser treatment
Study: 23761964
Drug: 0.15% GCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% GCV in situ ophthalmic gel
Study: 23761964
Drug: 0.15% GCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% GCV ophthalmic gel (control)
Study: 17058824
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin Pill (SBP) plus routine treatment
Study: 10804656
Drug: Different treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different treatments evaluated in randomized trials
Study: 2107242
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) nebulizer solution 1% administered three to four times daily for 8 weeks
Study: 19582579
Drug: Open-label lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label lansoprazole therapy (dose-titrated)
Study: 17884925
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion into biceps brachii
Study: 10323377
Drug: 4-6 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-6 mg/day lacidipine
Study: 10323377
Drug: 10-20 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-20 mg/day lisinopril
Study: 6271814
Drug: THC, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC, 5 mg
Study: 6271814
Drug: Prochlorperazine (PCPZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (PCPZ), 10 mg
Study: 6271814
Drug: THC, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC, 10 mg
Study: 6271814
Drug: THC, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC, 15 mg
Study: 31283756
Drug: Dofetilide, Moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide, Moxifloxacin (potassium channel blockers)
Study: 31283756
Drug: Mexiletine, Lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine, Lidocaine (sodium or calcium channel blockers)
Study: 31283756
Drug: Ranolazine (multichannel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (multichannel blocking drug)
Study: 31283756
Drug: Dofetilide +
Normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dofetilide + Mexiletine, Dofetilide + Lidocaine (drug combinations)
Study: 31283756
Drug: Tr40c (parameter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tr40c (parameter for differentiating drugs)
Study: 31283756
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tr10c to Tr100c in logistic regression model
Study: 25646201
Drug: 20‐mL/kg isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mL/kg isotonic saline bolus
Study: 21429094
Drug: Patch users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch users
Study: 21429094
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available patches
Study: 21429094
Drug: Non-patch users
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-patch users
Study: 20110012
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release (ER) pramipexole 0.75 mg
Study: 20110012
Drug: Single-dose ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ER pramipexole 0.375 mg (fasted state)
Study: 20110012
Drug: Single-dose ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ER pramipexole 0.375 mg (fed state)
Study: 20110012
Drug: Steady-state ER
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady-state ER pramipexole 0.375 to 4.5 mg (fasted state)
Study: 20110012
Drug: Steady-state ER
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady-state ER pramipexole 4.5 mg
Study: 17827952
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of infliximab with immunosuppressives at onset
Study: 15176536
Drug: Oral refeeding
Normalized name: Defend II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral refeeding
Study: 9601682
Drug: 5‐HT2A receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐HT2A receptor promoter polymorphism ‐1438G/A in patients with mood disorders
Study: 2684554
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment after 1 night
Study: 2684554
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment after 14 nights
Study: 2684554
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment after 42 nights
Study: 1102646
Drug: Antiheart antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiheart antibody (AHA) in high titer
Study: 1102646
Drug: Rise in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rise in titer to viral agents
Study: 30168415
Drug: Namilumab 300
Normalized name: Namilumab
DrugBank: Namilumab (DB13037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab 300 mg
Study: 28274253
Drug: Namilumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab (150 and 300 mg combined)
Study: 25567115
Drug: Anrukinzumab 200
Normalized name: Anrukinzumab
DrugBank: Anrukinzumab (DB12294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anrukinzumab 200 mg
Study: 25567115
Drug: Anrukinzumab 400
Normalized name: Anrukinzumab
DrugBank: Anrukinzumab (DB12294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anrukinzumab 400 mg
Study: 25567115
Drug: Anrukinzumab 600
Normalized name: Anrukinzumab
DrugBank: Anrukinzumab (DB12294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anrukinzumab 600 mg
Study: 25567115
Drug: Anrukinzumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anrukinzumab (all doses)
Study: 16469404
Drug: Corticosteroids (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (prednisolone 30 mg daily)
Study: 14506496
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day of fish oil (containing approximately 450 mg eicosapentaenoic acid and 350 mg docosahexaenoic acid)
Study: 10684911
Drug: Metronidazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (two 2-g doses)
Study: 26733410
Drug: SkQ1 1.55
Approvals — FDA: no, EMA: no, PMDA: no
Description: SkQ1 1.55 µg/mL
Study: 26733410
Drug: SkQ1 0.155
Approvals — FDA: no, EMA: no, PMDA: no
Description: SkQ1 0.155 µg/mL
Study: 26733410
Drug: 0.0 µg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 µg/mL (placebo)
Study: 24378998
Drug: Barostim therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barostim therapy
Study: 22503105
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) therapy with prednisone, initiated at 0.05 mg/kg/d, adjusted to maintain a trough blood level of 5 to 10 ng/mL for 1 year.
Study: 22503105
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) pulse cyclophosphamide (CTX) therapy with prednisone, initiated at 1 g/1.73 m(2) for a total dosage of 10 g/1.73 m(2) over 1 year.
Study: 20489031
Drug: Dalcetrapib (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib (900 mg) plus pravastatin
Study: 20489031
Drug: Dalcetrapib (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib (900 mg) plus rosuvastatin
Study: 20489031
Drug: Dalcetrapib (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib (900 mg) plus simvastatin
Study: 20489031
Drug: Dalcetrapib (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib (900 mg)
Study: 16126119
Drug: metformin+RSG 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin+RSG 4 mg b.i.d.
Study: 16126119
Drug: metformin+placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin+placebo
Study: 12198218
Drug: Post-haemodialysis administration
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-haemodialysis administration of vancomycin 15 mg/kg
Study: 9445320
Drug: rpro-UK (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rpro-UK (6 mg)
Study: 3981625
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg orally)
Study: 26918564
Drug: 28-day buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28-day buprenorphine taper
Study: 26918564
Drug: 56-day buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56-day buprenorphine taper
Study: 23421088
Drug: Emdogain treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emdogain treatment
Study: 15640389
Drug: REX-albuterol treatment
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: REX-albuterol treatment
Study: 9826114
Drug: (+)-UH232, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-UH232, single doses of 80 to 180 mg
Study: 71969
Drug: Flurbiprofen (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (150 mg to 200 mg daily)
Study: 71969
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg to 100 mg daily)
Study: 30053042
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of AL-794
Study: 30053042
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of AL-794
Study: 23666599
Drug: RAHelp online
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAHelp online intervention with weekly telephone support
Study: 21858614
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 0.75% ropivacaine (Group 5)
Study: 21858614
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.75% ropivacaine (Group 10)
Study: 17302069
Drug: Refined Xuefu
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined Xuefu Capsule (RXC) for 3 months
Study: 17302069
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Warfarin only)
Study: 17302069
Drug: Refined Xuefu
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined Xuefu Capsule (RXC)
Study: 15472166
Drug: Metformin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin administration (850 mg twice daily for 6 months)
Study: 9105740
Drug: Endoventricular streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoventricular streptokinase infusion (20,000 U/day for 96 hours)
Study: 3102167
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment applied 3-times daily for 4 to 10 days
Study: 3102167
Drug: Erythromycin (oral)
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin (oral) in normal dosage for skin infections
Study: 3102167
Drug: Flucloxacillin (oral)
Normalized name: cloxacillin Oral Capsule
DrugBank: Flucloxacillin (DB00301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin (oral) in normal dosage for skin infections
Study: 25956171
Drug: Five-drug ART
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug ART (tenofovir+emtricitabine+efavirenz+raltegravir+maraviroc, n=18)
Study: 25956171
Drug: Three-drug ART
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug ART (tenofovir+emtricitabine+efavirenz, n=18)
Study: 21375852
Drug: Hyaluronate-iodine soaked
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronate-iodine soaked gauze applied to wounds either daily or every other day depending on the amount of wound exudate.
Study: 17302372
Drug: Indomethacin (INDO)
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin (INDO) at a dosage of 1 mg/kg body weight, administered orally to CCoV-infected dogs.